CN115633736A - Feed additive for improving growth of spotted-brown broiler chickens, chicken feed and preparation method and application of chicken feed - Google Patents
Feed additive for improving growth of spotted-brown broiler chickens, chicken feed and preparation method and application of chicken feed Download PDFInfo
- Publication number
- CN115633736A CN115633736A CN202211326095.7A CN202211326095A CN115633736A CN 115633736 A CN115633736 A CN 115633736A CN 202211326095 A CN202211326095 A CN 202211326095A CN 115633736 A CN115633736 A CN 115633736A
- Authority
- CN
- China
- Prior art keywords
- spotted
- brown
- growth
- feed additive
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 78
- 239000003674 animal food additive Substances 0.000 title claims abstract description 39
- 235000013330 chicken meat Nutrition 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 5
- 150000007524 organic acids Chemical class 0.000 claims abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 18
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 239000001530 fumaric acid Substances 0.000 claims description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 3
- RIEABXYBQSLTFR-UHFFFAOYSA-N monobutyrin Chemical group CCCC(=O)OCC(O)CO RIEABXYBQSLTFR-UHFFFAOYSA-N 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- -1 butyrin ester Chemical class 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 235000012054 meals Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims 3
- 235000011087 fumaric acid Nutrition 0.000 claims 3
- AWHAUPZHZYUHOM-UHFFFAOYSA-N 1,2-dibutyrin Chemical compound CCCC(=O)OCC(CO)OC(=O)CCC AWHAUPZHZYUHOM-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 150000002238 fumaric acids Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 241000218671 Ephedra Species 0.000 abstract description 13
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract description 9
- 239000005639 Lauric acid Substances 0.000 abstract description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 abstract description 8
- 230000007413 intestinal health Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 4
- 230000029087 digestion Effects 0.000 abstract description 4
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 210000000987 immune system Anatomy 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000001965 increasing effect Effects 0.000 description 20
- 230000000968 intestinal effect Effects 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 14
- 102000003940 Occludin Human genes 0.000 description 12
- 108090000304 Occludin Proteins 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 230000009286 beneficial effect Effects 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 241000606125 Bacteroides Species 0.000 description 6
- 241000252983 Caecum Species 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 210000004534 cecum Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000192125 Firmicutes Species 0.000 description 5
- 239000002535 acidifier Substances 0.000 description 5
- 235000014590 basal diet Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012916 structural analysis Methods 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 241000605059 Bacteroidetes Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 150000003365 short chain fatty acid esters Chemical class 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100025255 Haptoglobin Human genes 0.000 description 2
- 241000566145 Otus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 102000011154 Tight junction protein ZO-1 Human genes 0.000 description 2
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108010027843 zonulin Proteins 0.000 description 2
- 241000927512 Barnesiella Species 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
The invention discloses a feed additive for improving the growth of spotted-brown broiler chickens, a chicken feed, and a preparation method and application thereof, and belongs to the technical field of feeds. The feed additive comprises the following components in parts by weight: 30-50 parts of lauric glyceride, 20-40 parts of butyrin, 20-40 parts of assistant and 1-10 parts of organic acid. According to the feed additive for improving the growth of the ephedra broiler chicken, the lauric acid glyceride and the butyric acid glyceride are introduced, the unique action mechanism of different carbon chain fatty acid glycerides is comprehensively utilized, and the effects of the lauric acid glyceride and the butyric acid glyceride are improved. Improve the digestion and absorption of the feed, promote the growth and weight increment, enhance the immune system and regulate the intestinal health.
Description
Technical Field
The invention belongs to the technical field of feeds, and particularly relates to a feed additive for improving the growth of spotted-brown broiler chickens, a chicken feed, and a preparation method and application thereof.
Background
At present, under the conditions of scale, intensification and high density, chicks are easily stimulated by various stress factors, the disease resistance of the body is weak, and the chicks are more easily threatened by various bacterial and viral diseases, so that a series of problems of growth obstruction, immunity inhibition, intestinal dysfunction and the like are caused, and the breeding benefit is seriously influenced. Because of the health degree of the chick culture stage, the subsequent breeding is greatly influenced. In the past, antibiotics and some medicines are often relied on, and the use of antibiotics and medicines may be harmful to human health. Therefore, the research and development of nonreactive technology and the guarantee of smooth culture are urgent.
In recent years, the drug resistance of special antibacterial drugs for animals is increased year by abusing antibiotics, which affects food safety and public health safety. In the antibiotic age after banning resistance, substitute products of antibiotics are actively searched, the culture gap is filled, and the method has potential huge economic benefit market. The existing market has a lot of antibiotics, including Chinese herbal medicines, acidifiers, enzyme preparations, essential oil, antibacterial peptide and the like, which have various characteristics but have some defects.
The alpha-glycerol monolaurate is a novel feed additive, has multiple functions of emulsifying property, bacteriostasis and virus resistance, regulating lipid metabolism, enhancing immunity, regulating intestinal flora structure and the like, and has no corrosivity, bad smell and taste. The feed additive can emulsify and disperse grease droplets in the feed into fine oil droplets, increase the contact area of lipase and the fine oil droplets and promote the digestion and absorption of fat; the fat envelope virus inhibitor has obvious inhibiting effect on fat envelope viruses such as blue ear diseases and the like in livestock and poultry; improving the lipid metabolism of the liver of an animal body, and slowing down or even treating the aggravation of the fatty liver; enhancing the immune system of the animal body and promoting the proliferation and differentiation of T lymphocytes; promoting the proliferation of beneficial bacteria in intestinal tract and inhibiting the proliferation of harmful bacteria. Is an ideal antibiotic substitute product and has wide development prospect.
The butyrin has good regulating effect on the intestinal health of animals. After being ingested by animals, the feed is not decomposed in the stomach, and after reaching the intestinal tract, the feed is decomposed into butyric acid and butyrin through the action of enzymes in the intestinal tract: (1) The energy is rapidly supplied to the intestinal epithelial cells, the growth of the small intestinal mucosa cells is effectively promoted, the maintenance and the repair of the intestinal mucosa are participated, and the integrity and the function of the intestinal mucosa cells are maintained; (2) The villus height of the intestinal tract of the animal is increased, the crypt depth is reduced, the ratio of the intestinal villus height to the crypt depth is increased, and the small intestine morphological structure is improved; (3) Reducing the pH value of intestinal tracts, inhibiting the growth of pathogenic bacteria such as escherichia coli, salmonella, clostridium perfringens and the like, promoting the proliferation of beneficial bacteria of lactic acid bacteria, and regulating the intestinal tract microecological balance of livestock and poultry; (4) Promoting the secretion of antibodies and immune cell proliferation of intestinal mucosa, enhancing the anti-stress and immunity capability of livestock and poultry, and reducing intestinal inflammation and other diseases.
Disclosure of Invention
Aiming at the problems, the invention aims to provide a feed additive for improving the growth of spotted-brown broiler chickens. The product has the advantages of good safety, reliability, cost performance and the like, the short-chain fatty acid ester product is compounded and used, the respective characteristics are comprehensively utilized, the short-chain fatty acid ester product generates interaction through a reasonable preparation scheme, the efficacy of the short-chain fatty acid ester product is improved, the antibacterial drug resistance can not be generated in animal bodies, and the use of antibiotics is effectively replaced.
The invention discloses a feed additive for improving the growth of spotted-brown broiler chickens, which comprises the following components in parts by weight:
30-50 parts of lauric glyceride, 20-40 parts of butyrin, 20-40 parts of silicon dioxide and 1-10 parts of compound acidifier.
In some embodiments of the invention, the following components are included in parts by weight:
40 parts of lauric glyceride, 30 parts of butyrin, 30 parts of silicon dioxide and 5 parts of compound acidifier.
In some embodiments of the invention, the glycerol monolaurate is primarily alpha-glycerol monolaurate.
In some embodiments of the invention, the glyceryl butyrate compositions are glyceryl monobutyrate, glyceryl dibutyrate and glyceryl tributyrate.
In some embodiments of the invention, the complex acidulant includes at least one of citric acid and fumaric acid.
In some embodiments of the invention, the mass ratio of the citric acid to the fumaric acid in the compound acidulant is (50-80) to (20-50).
In some embodiments of the invention, the mass ratio of citric acid to fumaric acid in the complex acidulant is 80:20.
The second aspect of the invention discloses a preparation method of the feed additive for improving the growth of spotted-brown broiler chicken, which is characterized by comprising the following steps:
s01, mixing the raw materials in proportion;
s02, spraying powder and granulating to obtain the solid granular feed additive.
The third aspect of the invention discloses a chicken feed comprising the feed additive for improving the growth of the spotted-brown broiler chickens, and preferably, the weight content of the feed additive for improving the growth of the spotted-brown broiler chickens is 0.01-1%.
The fourth aspect of the invention discloses application of the feed additive for improving the growth of spotted-brown broiler chickens in the first aspect in preparation of chicken feed.
The invention has the beneficial effects that:
1. the lauric acid glyceride and the butyric acid glyceride are introduced, the unique action mechanism of different carbon chain fatty acid glycerides is comprehensively utilized, and the effects of the lauric acid glyceride and the butyric acid glyceride are improved. Improve the digestion and absorption of the feed, promote the growth and weight increment, enhance the immune system and regulate the intestinal health.
2. The silicon dioxide is used as a carrier, and is subjected to solid granulation treatment by a spray granulation process. The high surface activity, the microporous structure and the large specific surface area of the silicon dioxide are utilized to efficiently load, the good biocompatibility and the gastrointestinal tract mucosa affinity of the silicon dioxide are kept, and the silicon dioxide has controlled and sustained release effects on the loaded materials.
3. The compound acidifier can improve the palatability of the feed, increase the appetite and increase the feed intake; the pH value in the stomach can be reduced, and the activity of pepsin is accelerated, so that the digestion and absorption of protein are promoted; can also improve gastrointestinal microflora, promote the reproduction and growth of beneficial bacteria and microorganisms such as lactobacillus, and inhibit the reproduction of harmful bacteria such as Escherichia coli and salmonella.
4. Test results show that the growth performance of the spotted-brown broiler chickens is remarkably improved during the high-density breeding period by adding the feed additive; reducing liver index, and maintaining liver health; increases the level of zonulin ZO-1 and occludin; improves species abundance, stability and beneficial bacteria level of intestinal flora, and promotes intestinal health.
Drawings
FIG. 1 shows the average end weight of 21d of spotted-brown broiler chickens treated by different dosages of alpha-GML;
FIG. 2 shows the 21d intestinal length of spotted-brown broiler chickens treated by different dosages of alpha-GML;
FIG. 3 is the liver index of spotted-brown broiler chickens treated by different dosages of alpha-GML;
FIG. 4 is thymus organ index of broiler chickens treated by different dosages of alpha-GML;
FIG. 5 is spleen organ index of broiler chickens treated with different dosages of alpha-GML;
FIG. 6 shows the protein expression of ZO-1, occludin in chicken intestinal tissues of each group;
FIG. 7 shows the expression levels of ZO-1 proteins in each group;
FIG. 8 shows the expression levels of occludin proteins in each group;
FIG. 9 is a plot of relative abundance accumulation for genus-level species;
FIG. 10 is a Venn diagram between treatment groups;
FIG. 11 shows the results of the structural analysis of the caecum flora, the structural analysis of the caecum flora and the analysis of the taxonomic composition of the genus level;
FIG. 12 is a graph of the level abundance of each set of samples;
fig. 13 is an alpha-diversity index, a.shannon index, b.simpson index, c.chao index and d.ace index;
FIG. 14 is a hierarchical clustering tree for each set of samples.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Unless otherwise specified, the examples and comparative examples are parallel tests with the same components, component contents, preparation steps, preparation parameters.
Raw materials: lauric acid glyceride (Kaiwen food development Co., ltd., guangzhou city, alpha-monolaurin content is more than or equal to 85%); butyrin (Weifang Keneng Biotechnology limited, mono-, di-and tributyrin > 50%); silica (Shanxi Tond chemical Co., ltd.); citric acid (Jungbunzlauer); fumaric acid (Zibovisus speciality chemical Co., ltd.). The compound acidulant comprises citric acid and fumaric acid, and the mass ratio of the citric acid to the fumaric acid is 80.
Examples
The feed additive for improving the growth of the spotted-brown broiler chicken adopts a powder spraying and granulating process and is prepared by mixing the raw materials in parts by weight in the following table into a solid granular feed additive.
| Lauric acid glyceride | Butyric acid glyceride | Silicon dioxide () | Compound acidifier (star) | |
| Example 1 | 30 | 40 | 20 | 1 |
| Example 2 | 50 | 20 | 40 | 10 |
| Example 3 | 40 | 30 | 30 | 5 |
| Example 4 | 35 | 35 | 30 | 7 |
| Example 5 | 40 | 40 | 20 (corn gluten meal) | 5 |
| |
40 | 40 | 20 (Bean pulp) | 5 |
| Example 7 | 43 | 35 | 24 | 6 (citric acid) |
| Example 8 | 43 | 35 | 24 | 6 (fumaric acid) |
| Example 9 | 43 | 35 | 24 | 6 (tartaric acid) |
| Comparative example 1 | 0 | 70 | 20 | 1 |
| Comparative example 2 | 70 | 0 | 20 | 1 |
Note: the unit of each datum is weight portion; note that: * Where specified, are the specified components, and are otherwise silica; note: * Where specifically indicated, are indicated components, otherwise are complex acidulants.
EXAMPLE 1 (Overall examination)
1200 1 day old spotted brown broiler chicks were selected and randomly divided into 4 treatment groups of 6 replicates each, with 50 replicates each. The control group was fed with basal diet, and the test group was fed with 0.05%, 0.1%, and 0.2% of the feed additive of example 1, respectively, based on the basal diet. The basic diet is a commercial product.
Specific test groups are shown in the following table:
TABLE 1 test grouping
The high-density cage-rearing chicken house is adopted for breeding, and during the experiment, a specially-assigned person is responsible for breeding according to the conventional breeding operation rules and immunizing according to the conventional immunization program.
After 21 days of cultivation, 30 chickens were randomly selected for each group for sample treatment and data collection, and experimental data were analyzed and processed.
Influence of 1 alpha-GML treatment for 21d on growth performance of spotted-brown broiler chicken
FIG. 1 shows the average end weight of 21d of spotted-brown broiler chickens treated by different dosages of alpha-GML. The test results are expressed as "mean ± standard deviation". "" indicates the degree of difference from the corresponding control (.: P <0.05,: P < 0.01), and the lower graph indicates the same method.
From the above figure, it can be seen that at 1-21d, compared with the blank control group, the average end weight of the alpha-GML group added with 500mg/kg of the basic ration is slightly increased but the difference is not significant, while the average end weight of the ephedra broilers is significantly increased by the alpha-GML group added with 1000mg/kg and 2000mg/kg of the basic ration, wherein the average end weight of the alpha-GML group added with 1000mg/kg of the basic ration is increased by 11.85% (p < 0.01), and the average end weight of the alpha-GML group added with 2000mg/kg of the basic ration is increased by 9.45% (p < 0.01). Compared with the group of 500mg/kg, the group added with 1000mg/kg of basal diet and 2000mg/kg of alpha-GML has 10.3 percent (p < 0.01) and 7.9 percent (p < 0.01) of average terminal weight, and the difference is very obvious. The results show that the addition of 1000mg/kg of alpha-GML and 2000mg/kg of alpha-GML in the basic daily ration can remarkably improve the growth performance of the spotted-brown broiler chickens during 1-21d of high-density culture.
Influence of 2 alpha-GML treatment for 21d on intestinal length and liver index of ephedra broiler chicken
Fig. 2 shows the 21d intestinal length of the spotted-brown broiler chickens treated by different dosages of alpha-GML, and fig. 3 shows the liver index of the spotted-brown broiler chickens treated by different dosages of alpha-GML.
As can be seen from FIG. 2I, at 1-21d, compared with the blank control group, the intestinal lengths of the alpha-GML groups added with 500mg/kg,1000mg/kg and 2000mg/kg of basal diet are slightly increased but the difference is not significant. Figure 3 shows that the liver index of the blank control group is similar to that of the alpha-GML group added with 500mg/kg (p > 0.05), while the liver index of the group added with 1000mg/kg,2000mg/kg alpha-GML is lower than that of the blank control group (p < 0.01), and the difference is very significant. The result shows that the addition of the alpha-GML in the daily ration hardly influences the intestinal length of the spotted-brown broiler, but the liver indexes of the alpha-GML group of 1000mg/kg and 2000mg/kg are remarkably reduced.
Influence of 3 alpha-GML treatment for 21d on immune organ index of spotted-brown broiler chicken
The figure is thymus organ index of the broiler chickens treated by different dosages of alpha-GML, and the figure 5 is spleen organ index of the broiler chickens treated by different dosages of alpha-GML.
The effect of the feed additive on the immune organ index of the spotted-brown broiler is shown in figure 4.
As shown in FIG. 4, the thymus organ index of the group with 1000mg/kg and 2000mg/kg of alpha-GML added to the diet was higher than that of the blank control group and that of the group with 500mg/kg of alpha-GML added to the diet (p > 0.05), and the difference was not significant. FIG. 5 shows that spleen organ index became large (p > 0.05) with no significant difference as the amount of daily ration added in the daily ration increased. The result shows that the addition of the alpha-GML in the daily ration can improve the immune organ index to a certain extent to enhance the immune function of the ephedra broiler chicken.
Influence of 4 alpha-GML treatment on serum biochemical indexes of the spotted-brown chickens by 21d on the influence of the feed additive on the serum biochemical indexes of the spotted-brown chickens, and the serum biochemical index results are shown in a table 2.
TABLE 2 Effect on serum biochemical indices of spotted-brown chicken
Note: * Indicating significant difference compared with the control group, p <0.05; * Indicates a very significant difference compared to the control group, p <0.01.
Compared with a control group, the activity of the lactate dehydrogenase added into the diet of the group with 1000mg/kg of alpha-GML is obviously improved by 55.4 percent (p is less than 0.05). Compared with the control group, the serum glutamic pyruvic transaminase activity is remarkably reduced by 23.1% (p is less than 0.05) and 21.4% (p is less than 0.05) by adding 500mg/kg and 2000mg/kg of alpha-GML in the diet respectively, and the serum glutamic pyruvic transaminase activity is remarkably reduced by 31.0% (p is less than 0.01) by adding 1000mg/kg of alpha-GML in the diet. The other indexes have no significant difference. Glutamate pyruvate transaminase is one of the most characteristic functional indexes of animal livers. When the liver is damaged by various factors, the hepatocytes cannot maintain their structural integrity and glutamate pyruvate transaminase permeates into the blood. Thus, increased glutamate pyruvate transaminase activity is a response to liver damage, and the detection of increased glutamate pyruvate transaminase activity in serum may indicate a disruption in the normal function of the liver. Experimental results show that the activity of serum glutamic pyruvic transaminase can be remarkably reduced by adding GML into the diet, which indicates that the liver function of the chicken is improved.
Influence of 5 alpha-GML treatment on 21d on Ephedra chicken intestinal proteins ZO-1 and occludin
FIG. 6 shows the protein expression of ZO-1,occludin in each group of chicken intestinal tissues. The corresponding relation between each group name and the addition amount of the alpha-GML is as follows: blank-0 mg/kg; low-500 mg/kg; medium-1000 mg/kg; the height is-2000 mg/kg. The same is applied below.
FIG. 7 shows the ZO-1 protein expression levels of each group, and FIG. 8 shows the occludin protein expression levels of each group.
The results of Western Blot analysis of the effect of alpha-GML treatment for 21d on the Ephedra chicken intestinal tight junction protein ZO-1, occludin are shown in 6,7,8. Analysis of the results shows that after the alpha-GML treatment is carried out for 21 days, the content of the ephedra broiler intestinal tight junction protein ZO-1 is increased and a certain dosage effect is presented. The low group has a significant increase in ZO-1 content (p < 0.05) over the blank group; the middle group has extremely obviously increased ZO-1 content (p < 0.01) compared with the blank group; the middle group, the high group, also had a very significant increase in ZO-1 content (p < 0.01) compared to the low group. The results show that after the alpha-GML treatment for 21 days, the content of the ephedra broiler intestinal tight junction protein occludin is also increased, and the difference is significant. Wherein the occludin content is significantly increased in the low and high groups compared to the blank group (p < 0.05); the occludin content was significantly increased in the middle group compared to the blank group (p < 0.01). The results show that after the alpha-GML is treated for 21 days, the content of ZO-1,occludin in intestinal tract of the ephedra broiler chicken is increased, and the difference is significant. .
7 influence of feed additive on caecum flora of ephedra broilers
FIG. 9 is a plot of relative abundance accumulation for genus-level species; as shown in the figure, the late trend of the accumulation curve of species in each genus level is flat, which indicates that the sampling quantity is sufficient, and the data analysis can be carried out.
FIG. 10 is a Venn diagram between treatment groups; as can be seen, a total of 290 OTUs were obtained for the four treatment groups, and 130 OUT were common for each treatment group, with 3 OTUs unique to the control group, 14 OUT unique to the low dose group, 6 OUT unique to the medium dose group, and 14 OUT unique to the high dose group.
FIG. 11 shows the results of structural analysis of the cecal flora, including structural analysis of the cecal flora and analysis of the taxonomic composition of the genus level; as can be seen from the figure, at the phylum level, the sum of 2 phyla, namely Bacteroidetes (Bacteroides) and Firmicutes (Firmicutes), reaches more than 92%. The control group was most abundant in Firmicutes and the α -GML treated group was most abundant in Bacteroidetes. The content of cecropin (bacteroides) in the control group is obviously lower than that in the low dose group (p < 0.05), the medium dose group (p < 0.05) and the high dose group (p < 0.05). As can be seen from the figure, at the genus level, the control group had significantly lower levels of Papanicolaria (Barnesiella) than those of the low dose group (p < 0.05), the medium dose group (p < 0.05), and the high dose group (p < 0.05), and significantly higher levels of Ruminococcaceae-UCG-014 than those of the low dose group (p < 0.05), the medium dose group (p < 0.05), and the high dose group (p < 0.05). Consistent with the gate level, the Bacteroides (Bacteroides) content of the control group was also significantly lower than that of the low dose group (p < 0.05), the medium dose group (p < 0.05), and the high dose group (p < 0.05).
FIGS. 12-14 are identity analyses, FIGS. 12-13 are alpha-diversity analyses, and FIG. 14 is beta-diversity analyses; wherein, fig. 12 is a grade abundance curve of each group of samples, and the species uniformity and species abundance of the control group, the low dose group and the high dose group are different according to the gentle degree of the later period of the curve and the range of the curve on the horizontal axis. FIG. 13 is an α -diversity index showing that there is a difference in α -diversity between the experimental group and the control group. The Shannon index of the control group is significantly lower than that of the low dose group (p < 0.05) and that of the high dose group (p < 0.05), indicating that the species uniformity of the control group is significantly lower than that of the low dose group and that of the high dose group. The control group had a significantly lower Chao index and ACE index than the low dose group (p < 0.05), indicating that the low dose group had a greater number of species than the control group. FIG. 14 is a hierarchical clustering tree of samples in each group, from which it can be seen that the low dose group, the high dose group are closest and then the medium dose group are close, the three groups are farthest from the control group. The differences of species compositions of the control group, the low dose group, the medium dose group and the high dose group are illustrated.
According to the analysis of the results, the alpha-GML treatment for 21d has great influence on the caecum of the ephedra broilers. The addition of alpha-GML in the daily ration increases the species abundance of the caecum, and the species diversity is also improved, thereby increasing the stability of the flora. According to phylum horizontal taxonomic composition analysis, the addition of alpha-GML reduces the ratio of firmicutes to bacteroidetes of the caecal flora, and according to previous researches, the increase of the ratio of firmicutes to bacteroides is not beneficial to the health of intestinal flora. Therefore, the addition of α -GML is beneficial for the growth of chickens. Bacteroides are significantly increased at the genus level, helping to break down food and produce the nutrients and energy required by the body. It also provides a degree of protection to the gut from invasive pathogens. Therefore, the alpha-GML treatment for 21d has a positive effect on the caecum of the ephedra broilers, and is beneficial to the intestinal health of the chickens.
To summarize: the alpha-GML can remarkably improve the growth performance of the spotted-brown broiler chickens during 1-21d of higher density culture period; reducing liver index, and maintaining liver health; increasing the level of zonulin ZO-1 and Occludin; improves species abundance, stability and beneficial bacteria level of intestinal flora, and promotes intestinal health.
Experimental example 2 (influence of different examples and comparative examples on growth performance of spotted-brown chickens)
The feed additives of examples and comparative examples were added to the feed of the basal diet in a weight ratio of 0.1% to prepare a chicken feed.
The influence of the feed additive on the growth performance of the spotted-brown broiler chickens was examined according to the method of experimental example 1, and the results are shown in table 3.
TABLE 3 influence on the growth Performance of Ephedra broilers
| 21d average last seed (g) | |
| Example 1 | 315 |
| Example 2 | 309 |
| Example 3 | 327 |
| Example 4 | 304 |
| Example 5 | 297 |
| Example 6 | 290 |
| Example 7 | 306 |
| Example 8 | 310 |
| Example 9 | 294 |
| Comparative example 1 | 286 |
| Comparative example 2 | 289 |
The results show that the feed additives of examples 1-9 have obvious effect (p < 0.01) on the growth performance of the spotted-brown chickens, and are superior to those of comparative examples 1 and 2, wherein the feed additive of example 1 is optimal (p < 0.01). The feed additive for improving the growth of the spotted-brown broiler chicken introduces the lauric acid glyceride and the butyric acid glyceride, comprehensively utilizes the unique action mechanism of different carbon chain fatty acid glycerides, and improves the effects of the lauric acid glyceride and the butyric acid glyceride.
While the preferred embodiments and examples of the present invention have been described in detail, the present invention is not limited to the embodiments and examples, and various changes can be made without departing from the spirit of the present invention within the knowledge of those skilled in the art.
Claims (10)
1. The feed additive for improving the growth of the spotted-brown broiler chicken is characterized by comprising the following components in parts by weight:
30-50 parts of lauric glyceride, 20-40 parts of butyrin, 20-40 parts of assistant and 1-10 parts of organic acid.
2. The feed additive for improving growth of spotted-brown broiler chickens according to claim 1, is characterized by comprising the following components in parts by weight:
40 parts of lauric glyceride, 30 parts of butyrin, 30 parts of auxiliary agent and 5 parts of organic acid.
3. The feed additive for improving growth of spotted-brown broiler chickens of claim 1 or 2, wherein the glycerol monolaurate is α -glycerol monolaurate as a main component.
4. The feed additive for improving growth of spotted-brown broiler chickens of claims 1-3, wherein said butyrin ester component is glycerol monobutyrate, glycerol dibutyrate and glycerol tributyrate.
5. The feed additive for improving growth of spotted-brown broiler chickens of any one of claims 1-4, wherein said additive is selected from at least one of silicon dioxide, corn protein powder and bean meal.
6. The feed additive for improving the growth of spotted-brown broiler chickens of claims 1-5, wherein said organic acid is selected from at least one of citric acid, fumaric acid and tartaric acid; preferably a complex acidulant of citric and fumaric acids.
7. The feed additive for improving the growth of spotted-brown broiler chickens according to any one of claims 1-6, wherein the mass ratio of citric acid to fumaric acid in the compound acidulant is (70-90) to (10-30), preferably 80:20.
8. The preparation method of the feed additive for improving the growth of spotted-brown broiler chickens according to any one of claims 1-7, characterized by comprising the following steps:
s01, mixing the raw materials in proportion;
s02, spraying powder and granulating to obtain the solid granular feed additive.
9. A chicken feed comprising the feed additive for improving the growth of spotted-brown broiler chickens according to any one of claims 1-8, preferably the weight content of the feed additive for improving the growth of spotted-brown broiler chickens is 0.01-1%.
10. The application of the feed additive for improving the growth of spotted-brown broiler chickens according to any one of claims 1-7 in the preparation of chicken feed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211326095.7A CN115633736A (en) | 2022-10-27 | 2022-10-27 | Feed additive for improving growth of spotted-brown broiler chickens, chicken feed and preparation method and application of chicken feed |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211326095.7A CN115633736A (en) | 2022-10-27 | 2022-10-27 | Feed additive for improving growth of spotted-brown broiler chickens, chicken feed and preparation method and application of chicken feed |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115633736A true CN115633736A (en) | 2023-01-24 |
Family
ID=84946145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211326095.7A Pending CN115633736A (en) | 2022-10-27 | 2022-10-27 | Feed additive for improving growth of spotted-brown broiler chickens, chicken feed and preparation method and application of chicken feed |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115633736A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105724821A (en) * | 2016-03-04 | 2016-07-06 | 江苏省家禽科学研究所 | Chicken feed composite acidifier as well as preparation method and application thereof |
| CN105916385A (en) * | 2013-11-20 | 2016-08-31 | 普罗维隆控股股份有限公司 | Animal feed comprising a combination of mono glycerides |
| CN112006165A (en) * | 2019-05-30 | 2020-12-01 | 龙岩新奥生物科技有限公司 | Emulsion composition, preparation method and application thereof |
-
2022
- 2022-10-27 CN CN202211326095.7A patent/CN115633736A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105916385A (en) * | 2013-11-20 | 2016-08-31 | 普罗维隆控股股份有限公司 | Animal feed comprising a combination of mono glycerides |
| CN105724821A (en) * | 2016-03-04 | 2016-07-06 | 江苏省家禽科学研究所 | Chicken feed composite acidifier as well as preparation method and application thereof |
| CN112006165A (en) * | 2019-05-30 | 2020-12-01 | 龙岩新奥生物科技有限公司 | Emulsion composition, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110982760B (en) | Bacillus belgii and application thereof in preventing and treating porcine diarrhea | |
| CN1314783A (en) | Method for increasing incorporation efficiency of omega-3 highly unsaturated fatty acid in poultry meat | |
| CN113812528A (en) | Plant extract additive for improving intestinal health of livestock and poultry | |
| Kang et al. | Effects of dietary supplementation with a chlorella by‐product on the growth performance, immune response, intestinal microflora and intestinal mucosal morphology in broiler chickens | |
| CN104277999A (en) | Novel multiple-effect Clostridium butyricum and application thereof in aspects of enhancing oxidation resistance of animals and improving meat quality | |
| CN116033923A (en) | Use of variovirax pathogens as a replacement therapy for coccidiosis | |
| Gülşen et al. | Effect of lactose and dried whey supplementation on growth performance and histology of the immune system in broilers | |
| CN116268192B (en) | Feed additive containing traditional Chinese medicine composition and application thereof | |
| CN111557389B (en) | Anti-bacterial Chinese herbal medicine enzyme composition and application thereof | |
| KR101157544B1 (en) | Feed Supplement and method for making Fermented Green Tea Probiotics | |
| KR101197682B1 (en) | Complex Feed Supplement and method for making Fermented Green Tea Probiotics | |
| CN115211492B (en) | Stress-resistant growth-promoting stress-relieving medicine for livestock and poultry, and preparation method and application thereof | |
| CN115633736A (en) | Feed additive for improving growth of spotted-brown broiler chickens, chicken feed and preparation method and application of chicken feed | |
| CN113229369B (en) | sn-2 saturated fatty acid active structured lipid composition and preparation method and application thereof | |
| CN114304413A (en) | Composite containing acidifying agent and preparation method thereof | |
| JPS6366191A (en) | Antibiotic ll-e 19020 alpha and beta | |
| Elbaz et al. | Effect of feeding corn distillers dried grains with solubles on growth performance, nutrients digestibility, plasma metabolites, immunological status, and intestinal health of broilers | |
| CN111149919A (en) | Glycerol butyrate compound for poultry as well as preparation method and application thereof | |
| CN113397041A (en) | Application of flood dragon wood in livestock breeding | |
| Ghavidel-Heydari et al. | The Effect of Fermented Sesame Meal or its Combination with Probiotics on the Performance, Carcass Triats, Blood Parameters, and Humoral Immunity in Growing Japanese Quails. | |
| CN1218656C (en) | Preparing method for left-eyed flounder compound feed | |
| Amechi | Feed value of fermented spent sorghum grains for broiler chickens | |
| CN111296673A (en) | Laying duck fermented feed and application thereof | |
| CN115105490B (en) | Plant essential oil composition for inhibiting clostridium perfringens and application thereof | |
| CN114606166B (en) | Bacteroides xylanisolvens and application thereof in preparation of products for treating or preventing alcoholic liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230124 |